In:
eLife, eLife Sciences Publications, Ltd, Vol. 6 ( 2017-08-10)
Abstract:
Prostate cancer is the second most common cancer in men around the world. The cancer relies on a protein called the androgen receptor in order to develop and grow. Currently, some of the most common treatments for prostate cancer, especially in its advanced stages, are drugs that block the activity of this receptor. However, such treatments are only successful for a limited period of time, and so alternative methods to inhibit this receptor are still needed. The androgen receptor must bind to a number of proteins to carry out its activity. These proteins include one called Bag-1L, which is also important for the development of prostate cancer. Stopping such a protein from binding with the androgen receptor might represent a new way to treat prostate cancer; but first it will be important to understand how this interaction actually regulates the activity of the receptor. Now, Cato et al. have analyzed samples of cancer cells that had been collected from 43 patients with prostate cancer and found that Bag-1L levels increase as the disease progresses. Looking at the patients’ medical records then revealed that therapies targeting the androgen receptor were less effective in people with high levels of Bag-1L. Conversely, altering, removing or inhibiting Bag-1L in prostate cancer cells grown in the laboratory made the receptor less active and made the cells grow slower. Further experiments went on to reveal that Bag-1L interacts with a regulatory region of the androgen receptor. Cato et al. note that this region remains largely unexplored therapeutically, because it has some unique structural properties that restrict how much it can interact with drug molecules. Targeting Bag-1L and stopping it from binding to this region of the androgen receptor would represent a different approach to inhibiting the androgen receptor and treating patients with prostate cancer. Together these new findings should provide pharmaceutical companies with much of the information they would require to immediately start screening for therapies that target Bag-1L. Ultimately, Cato et al. hope that any follow-up findings will benefit prostate cancer patients by improving the currently available treatments.
Type of Medium:
Online Resource
ISSN:
2050-084X
DOI:
10.7554/eLife.27159.001
DOI:
10.7554/eLife.27159.002
DOI:
10.7554/eLife.27159.003
DOI:
10.7554/eLife.27159.007
DOI:
10.7554/eLife.27159.004
DOI:
10.7554/eLife.27159.005
DOI:
10.7554/eLife.27159.006
DOI:
10.7554/eLife.27159.008
DOI:
10.7554/eLife.27159.015
DOI:
10.7554/eLife.27159.016
DOI:
10.7554/eLife.27159.009
DOI:
10.7554/eLife.27159.010
DOI:
10.7554/eLife.27159.011
DOI:
10.7554/eLife.27159.012
DOI:
10.7554/eLife.27159.013
DOI:
10.7554/eLife.27159.014
DOI:
10.7554/eLife.27159.017
DOI:
10.7554/eLife.27159.018
DOI:
10.7554/eLife.27159.019
DOI:
10.7554/eLife.27159.020
DOI:
10.7554/eLife.27159.021
DOI:
10.7554/eLife.27159.022
DOI:
10.7554/eLife.27159.023
DOI:
10.7554/eLife.27159.024
DOI:
10.7554/eLife.27159.025
DOI:
10.7554/eLife.27159.026
DOI:
10.7554/eLife.27159.027
DOI:
10.7554/eLife.27159.028
DOI:
10.7554/eLife.27159.029
DOI:
10.7554/eLife.27159.030
DOI:
10.7554/eLife.27159.031
DOI:
10.7554/eLife.27159.032
DOI:
10.7554/eLife.27159.033
DOI:
10.7554/eLife.27159.034
DOI:
10.7554/eLife.27159.035
DOI:
10.7554/eLife.27159.036
DOI:
10.7554/eLife.27159.040
DOI:
10.7554/eLife.27159.041
Language:
English
Publisher:
eLife Sciences Publications, Ltd
Publication Date:
2017
detail.hit.zdb_id:
2687154-3
Permalink